Shanghai Haohai Biological Technology Dividends and Buybacks
Dividend criteria checks 3/6
Shanghai Haohai Biological Technology is a dividend paying company with a current yield of 3.38% that is well covered by earnings.
Key information
3.4%
Dividend yield
1.7%
Buyback Yield
| Total Shareholder Yield | 5.1% |
| Future Dividend Yield | 4.6% |
| Dividend Growth | 13.1% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | HK$0.873 |
| Payout ratio | 85% |
Recent dividend and buyback updates
Recent updates
We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease
Jul 25
Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All
May 22Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Apr 17Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?
Feb 12Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Nov 14Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 28We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt
Mar 09These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Nov 25Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 30Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price
May 08Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Apr 19Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)
Mar 04Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
Mar 03Is Shanghai Haohai Biological Technology (HKG:6826) A Risky Investment?
Jan 10Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Oct 08Here's Why Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt Responsibly
Jul 07Analysts Have Just Cut Their Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Revenue Estimates By 14%
May 27These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Apr 04Investors Who Bought Shanghai Haohai Biological Technology (HKG:6826) Shares A Year Ago Are Now Up 58%
Mar 16Stability and Growth of Payments
Fetching dividends data
Stable Dividend: 6826 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 6826's dividend payments have increased, but the company has only paid a dividend for 9 years.
Dividend Yield vs Market
| Shanghai Haohai Biological Technology Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (6826) | 3.4% |
| Market Bottom 25% (HK) | 3.3% |
| Market Top 25% (HK) | 8.0% |
| Industry Average (Biotechs) | 1.2% |
| Analyst forecast (6826) (up to 3 years) | 4.6% |
Notable Dividend: 6826's dividend (3.38%) is higher than the bottom 25% of dividend payers in the Hong Kong market (3.3%).
High Dividend: 6826's dividend (3.38%) is low compared to the top 25% of dividend payers in the Hong Kong market (8.04%).
Earnings Payout to Shareholders
Earnings Coverage: At its current payout ratio (85.2%), 6826's payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonable cash payout ratio (56.8%), 6826's dividend payments are covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 10:30 |
| End of Day Share Price | 2025/01/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shanghai Haohai Biological Technology Co., Ltd. is covered by 16 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jingwei Qi | China Merchants Securities Co. Ltd. |
| Xiaofang Xu | Citic Securities Co., Ltd. |
| Eva Zhao | Citigroup Inc |